Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma
Authors:
- 18 April 2020
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 80 (8) , 813-819
Abstract
Cemiplimab (Libtayo®) is an antibody immunotherapy that stimulates an anti-cancer response via programmed cell death protein-1 (PD-1) blockade. It is the first approved treatment in the USA and EU for patients with locally advanced (laCSCC) or metastatic (mCSCC) cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiotherapy. Approval was based largely on positive results from the phase II EMPOWER-CSCC 1 trial in this patient population. In this pivotal trial, treatment with intravenous cemiplimab 3 mg/kg once every 2 weeks or 350 mg once every 3 weeks resulted in a clinically significant objective response rate across laCSCC and mCSCC patient groups. Furthermore, responses appear to be durable, as the median duration of response has not yet been reached. Similarly, the median overall survival has also not yet been reached as of the latest data cut-off date. The safety and tolerability profile of cemiplimab was acceptable, with most immune-related adverse events being clinically manageable with appropriate therapy or discontinuation of cemiplimab. Overall, cemiplimab has a durable, clinically significant effect and an acceptable tolerability and safety profile. As the first approved treatment for this indication, cemiplimab represents a welcome therapeutic advance for patients with advanced CSCC.Keywords
This publication has 18 references indexed in Scilit:
- European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and preventionEuropean Journal of Cancer, 2020
- Advanced Squamous Cell Carcinoma: What’s New?Current Dermatology Reports, 2019
- Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell CarcinomaAmerican Journal of Clinical Dermatology, 2019
- PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell CarcinomaNew England Journal of Medicine, 2018
- Cutaneous squamous cell carcinomaJournal of the American Academy of Dermatology, 2018
- The diverse functions of the PD1 inhibitory pathwayNature Reviews Immunology, 2017
- Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?Current Opinion in Oncology, 2017
- Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012JAMA Dermatology, 2015
- Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guidelineEuropean Journal of Cancer, 2015
- Cutaneous squamous cell carcinoma: Estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012Journal of the American Academy of Dermatology, 2013